Optimized HF Meds May Lessen MR Severity, Avoid Invasive Therapy

Patients with heart failure and mitral regurgitation should get at least 6 months of optimized guideline-directed medical therapy before invasive mitral repair is considered, researchers say.

Related Keywords

Germany ,United States ,North Carolina ,Massachusetts ,Washington ,Boston ,Duke University ,Berlin ,America ,American ,German ,Windtree Therapuetics ,Jamesl Januzzi ,Bristol Myers Squibb ,Bristol Myers ,G Michael Felker ,Amgen ,American Heart Association ,Boehringer Ingelheim ,Novartis ,Pfizer ,Astrazeneca ,Novartis Pharmaceuticals ,Cardiovascular Research ,Blood Institute ,National Heart ,Harvard Medical School ,German Center ,Imbria Pharmaceuticals ,Siemens ,Medtronic ,Trustee Of The American College Cardiology ,Massachusetts General Hospital ,Medscape Cardiology ,Kansas City Cardiomyopathy Questionnaire ,Heart Failure Society ,America Annual Scientific Meeting ,American College ,Applied Therapeutics ,Roche Diagnostics ,American Regent ,Cardiac Dimension ,Failure Society ,Breaking Clinical Trials Session ,Mitral Regurgitation ,Heart Failure ,Reduced Ejection ,Presented October ,Cardiovascular Imaging ,Ardiac Imaging ,V Imaging ,Echocardiography ,Echocardiogram ,Echo ,Valve Repair ,Renin Angiotensin System ,Renin Angiotensin Aldosterone System ,As Renin Angiotensin System ,Aas Renin Angiotensin Aldosterone System ,Clinical Research ,Clinical Trials ,Linical Studies ,Healthcare And Medical Technology ,Ealth And Medical Tech ,Health A ,